Table 1.
Clinical details of cases used in this study.
| Case no. | Sex/age | Disease course | Drug | Number of MR-visible WM lesions (FLAIR) |
|---|---|---|---|---|
| MS01 | M/32 | RRMS | GA | 1 |
| MS02 | M/32 | RRMS | GA | 18 |
| MS03 | M/38 | RRMS | GA | 55 |
| MS04 | F/52 | RRMS | GA | 22 |
| MS05 | F/29 | RRMS | GA | 21 |
| MS06 | F/26 | RRMS | GA | 17 |
| MS07 | F/33 | RRMS | No MSD | 51 |
| MS08 | F/20 | RRMS | IFNB | 53 |
| MS09 | F/41 | RRMS | IFNB | 36 |
| MS10 | M/38 | RRMS | DAC | 27 |
| MS11 | F/57 | RRMS | No MSD | 10 |
| MS12 | M/52 | RRMS | No MSD | 16 |
| MS13 | M/33 | RRMS | GA | 5 |
| CO01 | F/22 | NA | NA | NA |
| CO02 | F/62 | NA | NA | NA |
| CO03 | F/35 | NA | NA | NA |
| CO04 | M/39 | NA | NA | NA |
| CO05 | F/31 | NA | NA | NA |
| CO06 | F/38 | NA | NA | NA |
| CO07 | F/47 | NA | NA | NA |
| CO08 | M/54 | NA | NA | NA |
| CO09 | F/24 | NA | NA | NA |
| CO10 | M/22 | NA | NA | NA |
CO = control; MS = multiple sclerosis; NA = not applicable; RRMS = relapsing remitting MS; GA = Glatiramer Acetate; Interferon-B1a = IFNB; Daclizumab = DAC.